QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	2/18/2005 2:24:11 PM
	Read Replies (1) of 1321

Looks like an Acne treatment product is about to be approved... Key Data to be presented for the first time at the American Academy of Dermatology Conference VANCOUVER, Feb. 18 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announces data from three clinical studies presented at the American Academy of Dermatology conference in New Orleans demonstrating that the Company's acne product Aczone(TM) (5% dapsone topical gel) reduces the number and severity of all lesion types in acne patients with no significant safety issues. In the Phase III efficacy and safety trial reported 496 patients were enrolled. Of those, 330 were treated with 5% dapsone topical gel and 166 with a vehicle control gel. Results from this study demonstrate a significant reduction in the all lesion types (inflammatory, noninflammatory and total lesion counts) in patients using dapsone topical gel compared to the vehicle control group. Evaluations using a five point static Physicians Global Assessment Scale also showed improvements favoring the dapsone topical gel group. These results are consistent with the two pivotal Phase III trials which will be submitted for publication. The long-term safety study demonstrates that plasma levels of dapsone remained low throughout the 12-month study. Improvement in acne was seen early in the first month and throughout the study. A separate PK study showed that steady state plasma dapsone levels following topical use are more than 100 fold lower than following a single 100mg oral dapsone dose. "To date, in eight clinical studies over 4000 patients with acne have been treated with Aczone. The clinical data indicate that Aczone has the potential to become an important new prescription treatment for acne, pending approval by the FDA," said Mike Duncan, President of QLT USA, Inc. [SNIP]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next